Keane's Corner VL

Practical Guide to the use of Abiraterone in CRPC

Details
Practical Guide to the use of Abiraterone in Castration-resistant Prostate Cancer (CRPC) Thomas E. Keane, MD Professor and Chairman of the Department of Urology Medical University of South Carolina, Charleston, SC USA Click HERE to read the abstract BIOGRAPHY Thomas E. Keane, MBBCh, FRCSI, FACS specializes in managing prostate, bladder, and renal cancers. An avid researcher, Dr. Keane has served a...

Practical Guide to Immunotherapy in CRPC

Details
Review of Canadian Journal of Urology Supplement from April 2014 - Practical Guide to Immunotherapy in CRPC: The Use of Sipuleucel-T Immunotherapy Thomas E. Keane, MD Professor and Chairman of the Department of Urology Medical University of South Carolina, Charleston, SC USA Click HERE to read the abstract BIOGRAPHY Thomas E. Keane, MBBCh, FRCSI, FACS specializes in managing prostate, bladder, and...

Keane's Commentary - Results from ERSPC at 13 Years of Follow-up

Details
Commentary - Screening and Prostate Cancer Mortality: Results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 Years of Follow-up published in The Lancet Thomas E. Keane, MD Click HERE to read the abstract Click HERE to listen to one of the authors, Fritz H. Schröder MD, discuss this review

Most PCa Specialists Believe AS in Low-risk PCa is Effective and Underused

Details
Most PCa Specialists Believe AS in Low-risk PCa is Effective and Underused - Perspectives from the Editor-in-Chief (August 2014) Thomas E. Keane, MD Related Content : Click HERE to read the abstract for Perceptions of active surveillance and treatment recommendations for low-risk prostate cancer: Results from a national survey of radiation oncologists and urologists

Rates of Mgmt of Low-risk PCa with Observation Varies Widely Across Urologists and Rad Oncs

Details
Rates of Management of Low-risk Prostate Cancer with Observation Varies Widely Across Urologists and Radiation Oncologists - Perspectives from the Editor-in-Chief (August 2014) Thomas E. Keane, MD Related Content : Click HERE to read the abstract for Physician variation in management of low-risk prostate cancer: A population-based cohort study

Men with PCa and Recent Dx of Depression Less Likely to Undergo Definitive Tx & Experience Worse OS

Details
Men with Prostate Cancer and Recent Diagnosis of Depression are Less Likely to Undergo Definitive Treatment and Experience Worse Overall Survival - Perspectives from the Editor-in-Chief (July 2014) Thomas E. Keane, MD Related Content : Click HERE to read the abstract for Effect of depression on diagnosis, treatment, and mortality of men with clinically localized prostate cancer Click HERE to watch...

Primary ADT not Associated with Improved OS for Localized PCa

Details
Primary ADT is not Associated with Improved Long-term Overall or Disease-specific Survival for Men with Localized Prostate Cancer - Perspectives from the Editor-in-Chief (July 2014) Thomas E. Keane, MD Related Content : Click HERE to read the abstract for Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer Click HERE to listen to an interview...

Prostate Cancer Poster Session SES AUA 2014

Details
Prostate Cancer Poster Session SES AUA 2014 Thomas E. Keane, MD Related Content : Institutional modification of antibiotic prophylaxis protocol reduces infectious complications following transrectal ultrasound guided prostate biopsy Radical perineal prostatectomy: An old approach as a new alternative

Perspectives from the Editor-in-Chief - March 2014

Details
Perspectives from the Editor-in-Chief - March 2014 The following articles are discussed: Radical prostatectomy or watchful waiting in early prostate cancer Cell cycle progression score and treatment decisions in prostate cancer: Results from an ongoing registry Thomas E. Keane, MD

Keane's Corner - February 2014

Details
Perspectives from the Editor-in-Chief - February 2014 The following studies from GU Cancers Symposium 2014 are discussed: Enzalutamide in men with chemotherapy-naïve metastatic prostate cancer (mCRPC): Results of phase 3 PREVAIL study Ten- and 15-year prostate cancer-specific survival in patients with nonmetastatic high-risk prostate cancer randomized to lifelong hormone treatment alone or combine...
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe